Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07232004 | A Study to Evaluate How the Study Drug Moves Through the Body, Adverse Events, and How the Body Tolerates ABBV-547 Injections | PHASE1 | RECRUITING | 87 | — | — | Nov 24, 2025 | Sep 1, 2027 | Mar 5, 2026 | 2 | United States |
An AE is defined as any untoward medical occurrence in a patient or clinical investigation in which a participant is administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment.
| Arm | Type | Description |
|---|---|---|
| Group 1: ABBV-547 & Placebo | EXPERIMENTAL | Participants will receive either ABBV-547 or placebo. |
| Group 2: ABBV-547 & Placebo | EXPERIMENTAL | Participants will receive either ABBV-547 or placebo. |
| Group 3: ABBV-547 & Placebo | EXPERIMENTAL | Participants will receive either ABBV-547 or placebo. |
| Group 4: ABBV-547 & Placebo | EXPERIMENTAL | Participants will receive either ABBV-547 or placebo. |
| Group 5: ABBV-547 & Placebo | EXPERIMENTAL | Participants will receive either ABBV-547 or placebo. |
| Group 6: ABBV-547 & Placebo | EXPERIMENTAL | Participants will receive either ABBV-547 or placebo. |
| Name | Type | Description |
|---|---|---|
| ABBV-547 | DRUG | Injection |
| ABBV-547 Placebo | DRUG | Injection |
Inclusion Criteria: * A condition of general good health, based upon the results of a medical history, physical examination, vital signs, laboratory profile and a 12-lead electrocardiogram (ECG). * Part 1: BMI is \>= 18.0 to \<= 29.9 kg/m\^2 after rounding to the tenths decimal at Screening. BMI is...